Virtual Bioequivalence: a myth or coming reality? [Dissolution / BCS / IVIVC]
I was looking into the abstracts published after annual PAGE meeting (and had a pleasure to discuss it with some authors).
I collected some of them here for your review:
- In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone
- Automatic framework for bioequivalence studies from In Vitro test to In Vivo study design
- Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles
- Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies
- Bayesian knowledge integration for an in vitro–in vivo correlation (IVIVC) model
AFAIK regulatories are also interested and funding some of them.
What do you think? Is time of deconvolution over? Could we see new class A IVIVC using that approach soon?